CD47 and breast cancer: The largest study in which CD47 has been reported as a biomarker of worse prognosis was presented by Zhang et al.; they demonstrated that increased CD47 mRNA expression levels were associated with a significantly decreased probability of overall survival in two independent datasets, which together comprised 1,954 patients with breast cancer.